Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indapamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 1.00 |
| ▸ | CA2 | P00918 | 10/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CA6 | P23280 | 3/20 | 1.00 |
| ▸ | CA5A | P35218 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indapamide SCHEMBL41303 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL29372690 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL476213 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL2329030 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL163266 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL29496872 | 1.00 | CA1 (1.00) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL2989867 | 0.99 | CA1 (0.98) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL3159715 | 0.99 | CA1 (0.98) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL28261247 | 0.96 | CA1 (0.92) | CA1CA2CA12CA3CA4 | |
| Indapamide SCHEMBL16180488 | 0.94 | CA1 (0.89) | CA1CA2CA12CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3877402-B1 | COMBINATION TREATMENT FOR HYPERTENSION | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-07-16 | — | — | EP | claimed |
| CN-116800432-B | IIoT authentication scheme based on trusted execution environment and computational state credentials | 兰州大学 | 2024-12-17 | — | — | CN | claimed |
| EP-4103158-B1 | COMPOSITION COMPRISING RAMIPRIL AND INDAPAMIDE | ADAMED PHARMA S A (PL) | 2024-09-04 | — | — | EP | claimed |
| EP-4373474-A1 | BILAYER TABLET COMPRISING TELMISARTAN AND INDAPAMIDE | KRKA, D.D., Novo Mesto (SI) | 2024-05-29 | — | — | EP | claimed |
| EP-4101454-B1 | COMPOSITIONS FOR USE IN THE TREATMENT OF HYPERTENSION | THE GEORGE INST FOR GLOBAL HEALTH (AU) | 2024-04-10 | — | — | EP | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2023001880-A1 | BILAYER TABLET COMPRISING TELMISARTAN AND INDAPAMIDE | KRKA, D. D., NOVO MESTO (SI) | 2023-01-26 | — | — | WO | claimed |
| EP-4103158-A1 | COMPOSITION COMPRISING RAMIPRIL AND INDAPAMIDE | Adamed Pharma S.A. (PL) | 2022-12-21 | — | — | EP | claimed |
| EP-3573620-B1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | THE GEORGE INST FOR GLOBAL HEALTH (AU) | 2022-12-14 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | BAYER AG (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4642415-A1 | FLAT ROUND TABLET FEEDING SYSTEM FOR UNIGEL CAPSULE PRODUCTION, WITHOUT THE USE OF MEDICINE PREFILLING SYSTEM | Procaps SA (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250312396-A1 | Control of Cellular Redox Levels | MCKENNA ELIZABETH (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20220096388-A1 | APPARATUS AND PROCESS FOR SECONDARY ENCAPSULATION OF SOLID INCLUSIONS USING THE ROTARY DIE PROCESS | ARES CAPITAL CORPORATION, AS COLLATERAL AGENT | 2022-03-31 | — | — | US | disclosed |
| EP-3952846-A1 | ANALYTICAL METHOD FOR DETERMINING THE TOTAL AMOUNT OF A COATING POLYMER IN A DOSAGE FORM | R.P. Scherer Technologies, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027091-A1 | METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE | ALB, REN, TTR | CA1 3934/4885CA2 2850/4885CA12 2405/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | CA1 4864/4885CA2 4802/4885CA12 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.